Welcome to our dedicated page for Zynex news (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex stock.
Zynex, Inc. (ZYXI) is a Nevada-incorporated medical technology company that develops, manufactures, markets, and sells non-invasive medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for hospitals. The ZYXI news feed on Stock Titan aggregates company-issued press releases and other coverage that reflect both its operating activities and its financial and regulatory developments.
News about Zynex often highlights its medical device portfolio and corporate events. Company announcements describe its efforts to provide devices that support pain management and rehabilitation and to advance patient monitoring technologies, including multi-parameter and laser-based pulse oximetry. Updates have included submissions of products such as the NiCO laser pulse oximeter for FDA 510(k) review and subsequent strategic decisions to seek commercialization partners through its Zynex Monitoring Solutions subsidiary.
Investors following ZYXI news will also see disclosures related to the company’s financial performance, liquidity, and capital structure. Recent press releases and SEC-related announcements have discussed revenue trends, the impact of a temporary payment suspension from Tricare, restructuring measures, and the company’s evaluation of strategic alternatives with the assistance of external financial advisors and a special committee of the board.
Regulatory and capital markets developments are another key theme in Zynex news. In December 2025, Zynex announced that it had voluntarily entered into Chapter 11 court-supervised financial restructuring and later reported that Nasdaq had determined to delist its common stock as a result of the Chapter 11 cases. These items, along with leadership changes and board appointments, appear in the news flow and provide context on governance and oversight.
By reviewing the ZYXI news page, readers can track company communications on product strategy, restructuring progress, leadership changes, and listing status. This consolidated view helps users understand how Zynex’s medical technology focus intersects with its financial and regulatory path over time.
Zynex, Inc. (NASDAQ: ZYXI) reported strong financial results for Q2 2022, with revenue increasing 18% year-over-year to $36.8 million. Net income rose 19% to $3.3 million, yielding a diluted EPS of $0.08. Adjusted EBITDA also showed a significant increase of 16%, reaching $5.5 million. The company completed a $10 million share buyback and announced an additional program of $10 million. With the highest order volume recorded, Zynex reaffirms its full-year revenue guidance of $150-$170 million and third-quarter revenue expected between $40-$43 million.
Zynex, Inc. (NASDAQ: ZYXI) announced it will report its second quarter 2022 financial results on July 28, 2022. The management will also conduct a conference call at 4:15 p.m. ET to discuss financial results and provide corporate updates. Zynex specializes in non-invasive medical devices for pain management, rehabilitation, and monitoring. Founded in 1996, the company is focused on developing innovative medical technologies. Stakeholders can register for the webcast via the provided link.
Zynex, Inc. (NASDAQ: ZYXI) reported strong preliminary second-quarter results for 2022, revealing a 19% sequential increase in orders compared to Q1 2022 and a 10% increase over Q2 2021. The company anticipates revenue between $35.0 million and $38.0 million with adjusted EBITDA between $4.0 million and $6.0 million, aligning with its full-year guidance of $150 million to $170 million in revenue. Zynex emphasized efficient sales force execution, aiming for sustained profitable growth.
Zynex, Inc. (NASDAQ: ZYXI), a medical technology company, announced the change of its independent registered accounting firm from Plante & Moran to Marcum LLP, effective June 13, 2022. This decision followed a thorough evaluation process and received approval from the Board of Directors and Audit Committee. CEO Thomas Sandgaard expressed gratitude to Plante & Moran for their service over the past five years, indicating no disagreements or reportable events during that period. Zynex specializes in non-invasive medical devices for pain management and rehabilitation.
Zynex, Inc. (NASDAQ: ZYXI) announced a $10 million share buyback program effective from June 10, 2022, aimed at enhancing shareholder value and reflecting board confidence in the company's growth strategy. This program follows the completion of a previous buyback in less than 50 days. The purchase will be financed through existing cash balances and is not expected to materially impact capital levels. The board believes the current market value does not accurately represent the company's true value, making this buyback an attractive opportunity for capital deployment.
Zynex, a leading medical technology company, will participate in two key investor conferences in May 2022. The management will present virtually at the H.C. Wainwright Annual Global Investment Conference on May 24, 2022, at 7 AM ET. Additionally, Zynex will present at the UBS Global Healthcare Conference on May 25, 2022, at 12:15 PM ET. Investors can access webcasts of both events through the company's investor relations website. Zynex specializes in non-invasive medical devices for pain management, rehabilitation, and patient monitoring.
Summary not available.
Zynex reported a strong first quarter for 2022, with revenue increasing 29% year-over-year to $31.1 million. Net income soared 296% to $1.4 million, resulting in a diluted EPS of $0.03. Adjusted EBITDA surged 897% to $3.1 million. The company announced a $10 million share buyback program signaling confidence in its long-term strategy. For 2022, Zynex estimates full-year revenue between $150-$170 million and adjusted EBITDA of $25-$35 million.
Zynex, a medical technology company, will release its first quarter 2022 financial results on April 28, 2022. The conference call and webcast will be held at 4:15 p.m. ET to discuss the results and provide a corporate update. Zynex specializes in non-invasive medical devices for pain management and patient monitoring. For further details on the event, interested parties can register through a provided link.
Zynex, Inc. (NASDAQ: ZYXI) announced a $10 million share buyback program, effective from April 12, 2022 to April 11, 2023, aimed at enhancing shareholder value. CEO Thomas Sandgaard expressed confidence in the company’s growth potential, stating that the current market value does not reflect its true value. The buybacks will occur in the open market and will be funded through existing cash balances, without a significant impact on capital levels. As of April 8, 2022, the company had approximately 39.8 million shares outstanding.
FAQ
What is the current stock price of Zynex (ZYXI)?
What is the market cap of Zynex (ZYXI)?
